Unraveling the complex nature of prostate cancer stem cells

Cancer Biomarkers

Volumn 3, Issue 4-5, 2007, Pages 233-244

  Foshay, K ^a   Miera, A ^a   Stuart, A ^a   Fingland, N ^a   Mobley, S ^a   Gallicano, G I ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Biomarker; Cancer stem cell; Prostate

Indexed keywords

ALPHA2 INTEGRIN; ALPHA6 INTEGRIN; ANDROGEN; ANDROGEN RECEPTOR; BETA CATENIN; BREAST CANCER RESISTANCE PROTEIN; CD133 ANTIGEN; CD164 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; CYTOKERATIN 14; CYTOKERATIN 18; CYTOKERATIN 5; GLUTATHIONE TRANSFERASE P1; HERMES ANTIGEN; HISTONE DEACETYLASE INHIBITOR; METHYLTRANSFERASE INHIBITOR; MULTIDRUG RESISTANCE PROTEIN 1; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROSTATE SPECIFIC ANTIGEN; PROSTATE STEM CELL ANTIGEN; PROTEIN BCL 2; PROTEIN P63; SONIC HEDGEHOG PROTEIN; STEM CELL ANTIGEN 1; STROMAL CELL DERIVED FACTOR 1; TELOMERASE INHIBITOR; TRANSFORMING GROWTH FACTOR BETA; UNINDEXED DRUG; UVOMORULIN; VERY LATE ACTIVATION ANTIGEN 2;

ANTINEOPLASTIC ACTIVITY; CANCER CELL; CANCER GROWTH; CANCER STEM CELL; CARCINOGENESIS; CELL ADHESION; CELL DIFFERENTIATION; CELL ISOLATION; CELL POPULATION; CELL PROLIFERATION; CELL SURFACE; DISEASE MARKER; DNA MODIFICATION; DRUG EFFICACY; DRUG TARGETING; EPIGENETICS; GENE MUTATION; HEMATOPOIETIC STEM CELL; HORMONE ACTION; HORMONE RESPONSE; HUMAN; MALIGNANT TRANSFORMATION; METASTASIS POTENTIAL; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REVIEW; RNA INTERFERENCE; SIGNAL TRANSDUCTION; ANIMAL; BIOLOGICAL MODEL; MALE; NEOPLASM; PATHOLOGY; PROSTATE TUMOR;

ANIMALS; HUMANS; MALE; MODELS, BIOLOGICAL; NEOPLASMS, HORMONE-DEPENDENT; NEOPLASTIC STEM CELLS; PROSTATIC NEOPLASMS;

EID: 38449103496     PISSN: 15740153     EISSN: None     Source Type: Journal    
DOI: 10.3233/CBM-2007-34-507     Document Type: Review

References (99)

1. M. Al-Hajj and M.F. Clarke, Self-renewal and solid tumor stem cells, Oncogene 23 (2004), 7274-7282.
2. T.N. Alam, M.J. O'Hare, I. Laczko, A. Freeman, F. Al-Beidh, J.R. Masters and D.L. Hudson, Differential expression of cd44 during human prostate epithelial cell differentiation, J Histochem Cytochem 52 (2004), 1083-1090.
3. T.O. Alexsoni, S. Hitoshi, B.L. Coles, A. Bernstein and D. van der Kooy, Notch signaling is required to maintain all neural stem cell populations-irrespective of spatial or temporal niche, Dev Neurosci 28 (2006), 34-48.
4. P.A. Beachy, S.S. Karhadkar and D.M. Berman, Tissue repair and stem cell renewal in carcinogenesis, Nature 432 (2004), 324-331.
5. O.P. Berezovska, A.B. Glinskii, Z. Yang, X.M. Li, R.M. Hoffman and G.V. Glinsky, Essential role for activation of the polycomb group (pcg) protein chromatin silencing pathway in metastatic prostate cancer, Cell Cycle 5 (2006), 1886-1901.
6. G. Bhangal, S. Halford, J. Wang, R. Roylance, R. Shah and J. Waxman, Expression of the multidrug resistance gene in human prostate cancer, Urol Oncol 5 (2000), 118-121.
7. M. Blanchere, E. Saunier, C. Mestayer, M. Broshuis and I. Mowszowicz, Alterations of expression and regulation of transforming growth factor beta in human cancer prostate cell lines, J Steroid Biochem Mol Biol 82 (2002), 297-304.
8. C. Blanpain, W.E. Lowry, H.A. Pasolli and E. Fuchs, Canonical notch signaling functions as a commitment switch in the epidermal lineage, Genes Dev 20 (2006), 3022-3035.
9. P.E. Burger, X. Xiong, S. Coetzee, S.N. Salm, D. Moscatelli, K. Goto and E.L. Wilson, Sca-1 expression identifies stem cells in the proximal region of prostatic ducts with high capacity to reconstitute prostatic tissue, Proc Natl Acad Sci USA 102 (2005), 7180-7185.
10. T.P. Butler and P.M. Gullino, Quantitation of cell shedding into efferent blood of mammary adenocarcinoma, Cancer Res 35 (1975), 512-516.
11. B.K. Canales, Y. Li, M.G. Thompson, J.M. Gleason, Z. Chen, B. Malaeb, D.R. Corey, B.S. Herbert, J.W. Shay and K.S. Koeneman, Small molecule, oligonucleotide-bised telomerase template inhibition in combinition with cytolytic therapy in an in vitro androgen-independent prostate cancer model, Urol Oncol 24 (2006), 141-151.
12. B.Y. Chen, D.P. Lin, J.Y. Liu, H. Chang, P.H. Huang, Y.L. Chen and H.H. Chang, A mouse prostate cancer model induced by hedgehog overexpression, J Biomed Sci 13 (2006), 373-384.
13. C.S. Chen, S.C. Weng, P.H. Tseng, H.P. Lin and C.S. Chen, Histone acetylation-independent effect of histone deacetylase inhibitors on akt through the reshuffling of protein phosphatase 1 complexes, J Biol Chem 280 (2005), 38879-38887.
14. S.R. Chinni, S. Sivalogan, Z. Dong, J.C. Filho, X. Deng, R.D. Bonfil and M.L. Cher, Cxcl12/cxcr4 signaling activates akt-1 and mmp-9 expression in prostate cancer cells: The role of bone microenvironment-associated cxcl12, Prostate 66 (2006), 32-48.
15. A.T. Collins, P.A. Berry, C. Hyde, M.J. Stower and N.J. Maitland, Prospective identification of tumorigenic prostate cancer stem cells, Cancer Res 65 (2005), 10946-10951.
16. A.T. Collins, F.K. Habib, N.J. Maitland and D.E. Neal, Identification and isolation of human prostate epithelial stem cells based on alpha(2)beta(1)-integrin expression, J Cell Sci 114 (2001), 3865-3872.
17. V.L. Costa, R. Henrique and C. Jeronimo, Epigenetic markers for molecular detection of prostate cancer, Dis Markers 23 (2007), 31-41.
18. N. Craft, Y. Shostak, M. Carey and C.L. Sawyers, A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the her-2/neu tyrosine kinase, Nat Med 5 (1999), 280-285.
19. M.A. Dall'Era, L.D. True, A.F. Siegel, M.P. Porter, T.M. Sherertz and A.Y. Liu, Differential expression of cd10 in prostate cancer and its clinical implication, BMC Urol 7 (2007), 3.
20. S. Datta and M.W. Datta, Sonic hedgehog signaling in advanced prostate cancer, Cell Mol Life Sci 63 (2006), 435-448.
21. J.D. Doles, C.M. Vezina, R.J. Lipinski, R.E. Peterson and W. Bushman, Growth, morphogenesis, and differentiation during mouse prostate development in situ, in renal grafts, and in vitro, Prostate 65 (2005), 390-399.
22. A.W. Duncan, F.M. Rattis, L.N. DiMascio, K.L. Congdon, G. Pazianos, C. Zhao, K. Yoon, J.M. Cook, K. Willert, N. Gaiano and T. Reya, Integration of notch and writ signaling in hematopoietic stem cell maintenance, Nat Immunol 6 (2005), 314-322.
23. H.F. English, R.J. Santen and J.T. Isaacs, Response of glandular versus basal rat ventral prostatic epithelial cells to androgen withdrawal and replacement, Prostate 11 (1987), 229-242.
24. H. Enokida, H. Shiina, M. Igawa, T. Ogishima, T. Kawakami, W.W. Bassett, J.W. Anast, L.C. Li, S. Urakami, M. Terashima, M. Verma, M. Kawahana, M. Nakagawa, C.J. Kane, P.R. Carroll and R. Dahiya, Cpg hypermethylation of mdr1 gene contributes to the pathogenesis and progression of human prostate cancer, Cancer Res 64 (2004), 5956-5962.
25. G.S. Evans and J.A. Chandler, Cell proliferation studies in the rat prostate: Ii. The effects of castration and androgen-induced regeneration upon basal and secretory cell proliferation, Prostate 11 (1987), 339-351.
26. S. Forde, B.J. Tye, S.E. Newey, M. Roubelakis, J. Smythe, C.P. McGuckin, R. Pettengell and S.M. Watt, Endolyn (cd164) modulates the cxcl12-mediated migration of umbilical cord blood cd133+ cells, Blood 109 (2007), 1825-1833.
27. S.Y. Fuchs, A.V. Ougolkov, V.S. Spiegelman and T. Minamoto, Oncogenic beta-catenin signaling networks in colorectal cancer, Cell Cycle 4 (2005), 1522-1539.
28. T. Furutani, T. Watanabe, K. Tanimoto, T. Hashimoto, H. Koutoku, M. Kudoh, Y. Shimizi, S. Kato and H. Shikama, Stabilization of androgen receptor protein is induced by agonist, not by antagonists, Biochem Biophys Res Commun 294 (2002), 779-784.
29. M. Galsky and W.K. Kelly, The development of differentiation agents for the treatment of prostate cancer, Semin Oncol 30 (2003), 689-697.
30. G.V. Glinsky, O. Berezovska and A.B. Glinskii, Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer, J Clin Invest 115 (2005), 1503-1521.
31. M.A. Goodell, M. Rosenzweig, H. Kim, D.F. Marks, M. DeMaria, G. Paradis, S.A. Grupp, C.A. Sieff, R.C. Mulligan and R.P. Johnson, Dye efflux studies suggest that hematopoietic stem cells expressing law or undetectable levels of cd34 antigen exist in multiple species, Nat Med 3 (1997), 1337-1345.
32. C. Guo, D. Geverd, R. Liao, N. Hamad, C.M. Counter and D.T. Price, Inhibition of telomerase is related to the life span and tumorigenicity of human prostate cancer cells, J Urol 166 (2001), 694-698.
33. C.L. Hall, J. Dai, K.L. van Golen, E.T. Keller and M.W. Long, Type 1 collagen receptor ({alpha}2{beta}1) signaling promotes the growth of human prostate cancer cells within the bone, Cancer Res 66 (2006), 8648-8654.
34. N. Hasegawa, K. Mizutani, T. Suzuki, T. Deguchi and Y. Nozawa, A comparative study of protein profiling by proteomic analysis in camptothecin-resistant pc3 and camptothecin-sensitive incap human prostate cancer cells. Urol Int, 77 (2006). 347-354.
35. A.M. Havens, Y. Jung, Y.X. Sun, J. Wang, R.B. Shah, H.J. Buhring, K.J. Peinta and R.S. Taichman, The role of sialomucin cd164 (mgc-24v or endolyn) in prostate cancer metastasis, BMC Cancer 6 (2006 , 195.
36. Y. Hirabayashi and Y. Gotoh, Stage-dependent fate determination of neural precursor cells in mouse forebrain, Neurosci Res 51 (2005), 331-336.
37. C. Hirschmann-Jax, A.E. Foster, G.G. Wulf, J.G. Nuchtern, T.W. Jax, U. Gobel, M.A. Goodell and M.K. Brenner, A distinct "side population" of cells with high drug efflux capacity in human tumor cells, Proc Natl Acad Sci USA 101 (2004), 14228-14233.
38. D.L. Hudson, Epithelial stem cells in human prostate growth and disease, Prostate Cancer Prostatic Dis 7 (2004), 188-194.
39. W.J. Huss, D.R. Gray, N.M. Greenberg, J.L. Mohler and G.J. Smith, Breast cancer resistance protein-mediated efflux of androgen in putative benign and malignant prostate stem cells, Cancer Res 65 (2005), 6640-6650.
40. K.A. Iczkowski, W. Huang, R. Mazzucchelli, C.G. Pantazis, G.R. Stevens and R. Montironi, Androgen ablation therapy for prostate carcinoma suppresses the immunoreactive telomerase subunit htert, Cancer 100 (2004), 294-299.
41. J.T. Isaacs and D.S. Coffey, Etiology and disease process of benighn prostatic hyperplasia, Prostate 2 (1989), 33-50.
42. J.J. Jacobs, K. Kieboom, S. Marino, R.A. DePinho and M. van Lohuizen, The oncogene and polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus, Nature 397 (1999), 164-168.
43. M. Jaggi, S.L. Johansson, J.J. Baker, L.M. Smith, A. Galich and K. C. Balaji, Aberrant expression of e-cadherin and beta-catenin in human prostate cancer, Urol Oncol 23 (2005), 402-406.
44. S.S. Karhadkar, G.S. Bova, N. Abdallah, S. Dhara, D. Gardner, A. Maitra, J.T. Isaacs, D.M. Berman and P.A. Beachy, Hedgehog signalling in prostate regeneration, neoplasia and metastasis, Nature 431 (2004), 707-712.
45. I.Y. Kim, H.J. Ahn, D.J. Zelner, J.W. Shaw, S. Lang, M. Kato, M.G. Oefelein, K. Miyazono, J.A. Nemeth, J.M. Kozlowski and C. Lee, Loss of expression of transforming growth factor beta type i and type ii receptors correlates with tumor grade in human prostate cancer tissues, Clin Cancer Res 2 (1996), 1255-1261.
46. A.G.J. Knudson, L.C. Strong and D.E. Anderson, Heredity and cancer in man, Prog Med Genet 9 (1973), 113-158.
47. K.S. Koeneman, Prostate cancer stem cells, telomerase biology, epigenetic modifiers, and molecular systemic therapy for the androgen-independent lethal phenotype, Urol Oncol 24 (2006 , 119-121.
48. R. Kopan and H. Weintraub, Mouse notch: Expression in hair follicles correlates with cell fate determination, J Cell Biol 121 (1993), 631-641.
49. P. Kukreja, A.B. Abdel-Mageed, D. Mondal, K. Liu and K.C. Agrawal, Up-regulation of cxcr4 expression in pc-3 cells by stromal-derived factor-1alpha (cxc112) increases endothelial adhesion and transendothelial migration: Role of mek/erk signaling pathway-dependent nf-kappab activation, Cancer Res 65 (2005), 9891-9898.
50. J.S. Lam and R.E. Reiter, Stem cells in prostate and prostate cancer development, Urol Oncol 24 (2006), 131-140.
51. F. Li, B. Tiede, J. Massague and Y. Kang, Beyond tumorigenesis: Cancer stem cells in metastasis, Cell Res 17 (2007), 3-14.
52. S. Li, J. Crothers. C.M. Haqq and E.H. Blackburn, Cellular and gene expression responses involved in the rapid growth inhibition of human cancer cells by ma interference-mediated depletion of telomerase ma, J Biol Chem 280 (2005), 23709-23717.
53. X. Li, C. Wong, R. Mysel, G. Slobodov, A. Metwalli, J. Kruska, C.S. Manatt, D.J. Culkin, B.P. Kropp and H.K. Lin, Screening and identification of differentially expressed transcripts in circulating cells of prostate cancer patients using suppression subtractive hybridization, Mol Cancer 4 (2005), 30.
54. J.C. Lin, S.Y. Chang, D.S. Hsieh, C.F. Lee and D.S. Yu, The association of id-1, mif and gstpi with acquired drug resistance in hormone independent prostate cancer cells, Oncol Rep 13 (2005), 983-988.
55. I.V Litvinov, D.J. Vander Griend, Y. Xu, L. Antony, S.L. Dalrymple and J.T. Isaacs, Low-calcium serum-free defined medium selects for growth of normal prostatic epithelial stem cells, Cancer Res 66 (2006), 8598-8607.
56. S. Makino, The role of tumor-stem cells in regrowth of the tumor following drastic applications, Acta Unio Int Contra Cancrum 15 (1959), 196-198.
57. B.S. Mimeault M, Functions of tumorigenic and migrating cancer progenitor cells in cancer progression and metastasis and their therapeutic implications, Cancer Metastasis Rev Feb 2 (2007), Epub ahead of print.
58. A.V. Molofsky, R. Pardal, T. Iwashita, I.K. Park, M.F. Clarke and S.J. Morrison, Bmi-1 dependence distinguishes neural stem cell self-renewal from progenitor proliferation, Nature 425 (2003), 962-967.
59. H. Okada, A. Tsubura, A. Okamura, H. Senzaki, Y. Naka, Y. Komatz and S. Morii, Keratin profiles in normal/hyperplastic prostates and prostate carcinoma, Virchows Arch A Pathol Anat Histopathol 421 (1992), 157.
60. C.A. Olsson, G.M. de Vries, R. Buttyan and A.E. Katz, Reverse transcriptase-polymerase chain reaction assays for prostate cancer, Urol Clin North Am 24 (1997), 367-378.
61. L. Patrawala, T. Calhoun, R. Schneider-Broussard, H. Li, B. Bhatia, S. Tang, J.G. Reilly, D. Chandra, J. Zhou, K. Claypool, L. Coghlan and D.G. Tang, Highly purified cd44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells, Oncogene 25 (2006), 1696-1708.
62. L. Patrawala, T. Calhoun, R. Schneider-Broussard, J. Zhou, K. Claypool and D.G. Tang, Side population is enriched in tumorigenic, stem-like cancer cells, whereas abcg2+ and abcg2 - cancer cells are similarly tumorigenic, Cancer Res 65 (2005), 6207-6219.
63. K.J. Pienta and D. Bradley, Mechanisms underlying the development of androgen-independent prostate cancer, Clin Cancer Res 12 (2006), 1665-1671.
64. M.Z. Ratajczak, E. Zuba-Surma, M. Kucia, R. Reca, W. Wojakowski and J. Ratajczak, The pleitropic effects of the sdf-l-cxcr4 axis in organogenesis, regeneration and tumorigenesis, Leukemia 20 (2006), 1915-1924.
65. R.E. Reiter, Z. Gu, T. Watabe, G. Thomas, K. Szigeti, E. Davis, M. Wahl, S. Nisitani, J. Yamashiro, M.M. Le Beau, M. Loda and O.N. Witte, Prostate stem cell antigen: A cell surface marker overexpressed in prostate cancer, Proc Natl Acad Sci USA 95 (1998), 1735-1740.
66. G.D. Richardson, C.N. Robson, S.H. Lang, D.E. Neal, N.J. Maitland and A.T. Collins, Cd133, a novel marker for human prostatic epithehal stem cells, J Cell Sci 117 (2004), 3539-3545.
67. D.J. Rossi and I.L. Weissman, Pten, tumorigenesis, and stem cell self-renewal, Cell 125 (2006). 229-231.
68. S.N. Satin, P.E. Burger, S. Coetzee, K. Goto, D. Moscatelli and E.L. Wilson, Tgf-beta maintains dormancy of prostatic stem cells in the proximal region of ducts, J Cell Biol 170 (2005), 81-90.
69. S. Santagata, F. Demichelis, A. Riva, S. Varambally, M.D. Hofer, J.L. Kutok, R. Kim, J. Tang, J.E. Montie, A,M. Chinnaiyan, M.A. Rubin and J.C. Aster, Jaggedl expression is associated with prostate cancer metastasis and recurrence, Cancer Res 64 (2004), 6854-6857.
70. N. Sharifi, E.M. Hurt, B.T. Kawasaki and W.L. Farrar, Tgfbr3 loss and consequences in prostate cancer, The Prostate 67 (2007), 301-311.
71. N. Sharifi, B.T. Kawasaki, E.M. Hurt and W.L. Farrar, Stem cells in prostate cancer: Resolving the castrate-resistant conundrum and implications for hormonal therapy, Cancer Biol Ther 5 (2006), 901-906.
72. A. Shaw and W. Bushman, Hedgehog signaling in the prostate, J Urol 177 (2007), 832-838.
73. A. Shiras, S. Chettiar, V. Shepal, G. Rajendran, R. Prasad and P. Shastry, Spontaneous transformation of human adult non-tumorigenic stem cells to cancer stem cells is driven by genomic instability in a human model of glioblastoma, Stem Cells (2007).
74. X. Song, G.B. Call, D. Kirilly and T. Xie, Notch signaling controls germline stem cell niche formation in the drosophila ovary, Development 134 (2007), 1071-1080.
75. J. Southgate, P. Haraden and L.K. Trejdosiewicz, Cytokeratin expression patterns in normal and malignant urothelium: A review of the biological and diagnostic implications, Histol Histopathol 14 (1999), 657-664.
76. M. Suenaga, H. Soda, M. Oka, A. Yamaguchi, K. Nakatomi, K. Shiozawa, S. Kawabata, T. Kasai, Y. Yamada, S. Kamihira, C. Tei and S. Kohno, Histone deacetylase inhibitors suppress telomerase reverse transcriptase mrna expression in prostate cancer cells, Int J Cancer 97 (2002 , 621-625.
77. Y.X. Sun, M. Fang, J. Wang, C.R. Cooper, K.J. Pienta and R.S. Taichman, Expression and activation of alpha(v)beta(3) integrins by sdf-1/cxc12 increases the aggressiveness of prostate cancer cells, Prostate 67 (2007), 61-73.
78. D.G. Tang, L. Patrawala, T. Calhoun, B. Bhatia, G. Choy, R. Schneider-Broussard and C. Jeter, Prostate cancer stem/progenitor cells: Identification, characterization, and implications, Molecular Carcinogenesis 46 (2607), 1-14.
79. P. Thelen, S. Schweyer, B. Hemmerlein, W. Wuttke, F. Seseke and R.H. Ringert, Expressional changes after histone deacetylase inhibition by valproic acid in lncap human prostate cancer cells, Int J Oncol 24 (2004), 25-31.
80. E.J. Tokar, B.B. Ancrile, G.R. Cunha and M.M. Webber, Stem/progenitor and intermediate cell types and the origin of human prostate cancer, Differentiation 73 (2005), 463-473.
81. L.C. Trotman, M. Niki, Z.A. Dotan, J.A. Koutcher, A. Di Cristofano, A. Xiao, A.S. Khoo, P. Roy-Burman, N.M. Greenberg, T. Van Dyke, C. Cordon-Cardo and P.P. Pandolfi, Pten dose dictates cancer progression in the prostate, PLoS Biol 1 (2003), E59.
82. A. Tsujimura, Y. Koikawa, S. Salm, T. Takao, S. Coetzee, D. Moscatelli, E. Shapiro, H. Lepor, T.T. Sun and E.L. Wilson, Proximal location of mouse prostate eHithelial stem cells: A model of prostatic: homeostasis, J Cell Biol 157 (2002), 1257-1265.
83. M.E. Valk-Lingbeek, S.W. Bruggeman and M. van Lohuizen, Stem cells and cancer, the polycomb connection, Cell 118 (2004), 409-418.
84. N.M. van der Lugt, J. Domen, K. Linders, M. van Roon, E. Robanus-Maandag, H. te Riele, M. van der Valk, J. Deschamps, M. Sofroniew, M. van Lohuizen et al., Posterior transformation, neurological abnormalities, and severe hematopoietic defects in mice with a targeted deletion of the bmi-1 proto-oncogene, Genes Dev 8 (1994), 757-769.
85. G. van Leenders, H. Dijkman, C. Hulsbergen-van de Kaa, D. Ruiter and J. Schalken, Demonstration of intermediate cells during human prostate epithelial differentiation in situ and in vitro using triple-staining confocal scanning microscopy, Lab Invest 80 (2000), 1251-1258.
86. A.P. Verhagen, F.C. Ramaekers, T.W. Aalders, H.E. Schaafsma, F.M. Debruyne and J.A. Schalken, Colocalization of basal and luminal cell-type cytokeratins in human prostate cancer, Cancer Res 52 (1992), 6182.
87. M. Verras and Z Sun, Roles and regulation of wnt signaling and beta-catenin in prostate cancer, Cancer Lett 237 (2006), 22-32.
88. T. Visakorpi, E. Hyytinen, P. Koivisto, M. Tanner, R. Keinanen, C. Palmberg, A. Palotie, T. Tammela, J. Isola and O.P. Kallioniemi, In vivo amplification of the androgen receptor gene and progression of human prostate cancer, Nat Genet 9 (1995), 401-406.
89. J. Wang, R. Loberg and R.S. Taichman, The pivotal role of cxc112 (sdf-1)/ cxcr4 axis in bone metastasis, Cancer Metastasis Rev 25 2006), 573-587.
90. S. Wang, A.J. Garcia, M. Wu, D.A. Lawson, O.N. Witte and H. Wu, Pten deletion leads to the expansion of a prostatic stem/progenitor cell subpopulation and tumor initiation, Proc Natl Acad Sci USA 103 (2006), 1480-1485.
91. J.J. Westendorf and L. Hoeppner, Type i collagen receptor ({alpha}2{beta}1) signaling promotes the growth of human prostate cancer cells within the bone hall cl, dai j, van golen kl, keller et, long mw, departments of urolcgy and internal medicine, university of michigan, mi, Urol Oncol 25 (2007), 179-180.
92. M.D. Westfall and J.A. Pietenpol, P63: Molecular complexity in developmept and cancer, Carcinogenesis 25 (2004), 857-864.
93. L. Xin, D.A. Lawson and O.N. Witte. The sca-1 cell surface marker enriches for a prostate-regenerating cell subpopulation that can initiate prostate tumorigenesis, Proc Natl Acad Sci USA 102 (2005), 6942-6947.
94. O.H. Yilmaz, R. Valdez, B.K. Theisen, W. Guo, D.O. Ferguson, H. Wu and S.J. Morrison, Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells, Nature 441 (2006), 415-482.
95. T. Yoshino, H. Shiina, S. Urakami, N. Kikuno, T. Yoneda, K. Shigeno and M. Igawa, Bcl-2 expression as a predictive marker of hermone-refractory prostate cancer treated with taxane-based chemotherapy, Clin Cancer Res 12 (2006), 6116-6124.
96. D.S. Yu, J.C. Lin, D.S. Hsieh, S.Y. Chang and C.F. Lee, Modulation of mdr-1 gene by mif and gstpi with drug resistance generation in hormone independent prostate cancer, Arch Androl 52 (2006), 283-291.
97. M. Zayzafoon, S.A. Abdulkadir and J.M. McDonald, Notch signaling and erk activation are important for the osteomimetic properties of prostate cancer bone metastatic cell lines, J Biol Chem 279 (2004), 3662-3670.
98. Y. Zhang, Z. Wang, F. Ahmed, S. Banerjee, Y. Li and F.H. Sarkar, Down-regulation of jagged-1 induces cell growth inhibition and s phase arrest in prostate cancer cells, Int J Cancer 119 (2006), 2071-2077.
99. B.L. Ziober, C.S. Lin and R.H. Kramer, Laminin-binding integrins in tumor progression and metastasis, Semin Cancer Biol 7 (1996), 119-128.